Outcomes of Oral Antidiabetic Drugs in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Nationwide Target Trial Emulation Study
In patients with concurrent T2DM and MASLD, SGLT2 inhibitors demonstrated better cardiovascular outcomes compared to other OADs. These findings suggest that SGLT2 inhibitors may be the preferred OAD choice for cardiovascular risk reduction in this high-risk population.
Authors
- Yeonjin Kim (ORCID: https://orcid.org/0009-0005-0620-9993)
- Bokyung Koo
- S Romeo
- Sae Kyung Joo (ORCID: https://orcid.org/0000-0002-4615-7607)
- W. Lee
- Heejoon Jang
- Dong Hyeon Lee
- Yoo Kyoung Lim
- Won Kim
Institutions
- Seoul National University (KR)
- Seoul Metropolitan Government (KR)
- Karolinska Institutet (SE)
- SNUH SMG-SNU Boramae Medical Center (KR)
Publication Details
- Journal
- Clinical and Molecular Hepatology
- Published
- 2026-01-06
- DOI
- https://doi.org/10.3350/cmh.2025.1006
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Research Foundation
- Korean Association for the Study of the Liver